Navigation Links
Galectin Therapeutics Reports Full Year and Fourth Quarter 2012 Financial Results
Date:3/29/2013

NORCROSS, Ga., March 29, 2013 /PRNewswire/ -- Galectin Therapeutics Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today reported its financial results for the full year and fourth quarter, ended December 31, 2012. These results are included in the Company's Quarterly Report on Form 10-K, which has been filed with the SEC.

"It was a year of great progress for our Company," said Peter G. Traber , M.D., Chief Executive Officer, President and Chief Medical Officer, Galectin Therapeutics. "We completed a significant fundraising and our stock was listed on the NASDAQ Capital Market earlier in the year, we relocated our headquarters to Norcross, Georgia during the fourth quarter, and we made significant advances developing our fibrosis program. We have continued this progress into 2013, having submitted an IND for GR-MD-02 in January and received the FDA's ok that we could proceed with a Phase 1 clinical trial. We expect to initiate a Phase 1 clinical trial of GR-MD-02 during the second quarter of 2013 in patients with nonalcoholic steatohepatitis (NASH) and liver fibrosis and have engaged CTI Clinical Trial Services to provide services related to this trial. The novel mechanism of action of GR-MD-02, in combination with compelling preclinical data, gives us great hope that this compound may ultimately meet the needs of patients with this deadly disease that currently has no approved therapeutic options."

At December 31, 2012, the Company had $9.4 million of non-restricted cash and cash equivalents available to fund future operations.  The Company believes that with the funds on hand at December 31, 2012, there is sufficient cash to fund core operations and planned research and development through the first quarter of 2014.

For the fourth quarter of 2012, the Company reported a net lo
'/>"/>

SOURCE Galectin Therapeutics Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Galectin-3 Assessed as a Biomarker of Heart Failure: Key Clinical Trial Findings Published by Dove Medical Press
2. Cell Therapeutics, Inc. Reports Results of Annual Meeting of Shareholders
3. Nile Therapeutics Reports 2011 Third Quarter Financial Results
4. Nile Therapeutics Announces Top-Line Results in Clinical Trial Evaluating the Subcutaneous Infusion of Cenderitide, Meets Primary Endpoint
5. Fate Therapeutics Strengthens Its iPSC Platform
6. Amsterdam Molecular Therapeutics Provides Business Update for the Third Quarter 2011
7. MarketsandMarkets: Global Prostate Cancer Therapeutics Market worth $6,457 Million by 2020
8. MarketsandMarkets: Leukemia Therapeutics Market Worth $11.3 Billion by 2020
9. Roche Signs Agreement with PTC Therapeutics to Advance Treatment for Spinal Muscular Atrophy (SMA)
10. Echo Therapeutics Announces Positive Results of Clinical Trial of its Symphony® Transdermal Continuous Glucose Monitoring (tCGM) System in Patients With Type 1 and Type 2 Diabetes
11. Aratana Therapeutics Completes $15 Million Series B Financing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... 2014 The largest international professional organization of ... therapeutic derivatives thereof has endorsed an educational program ... the challenges of adulterated herb and botanical products. ... The Society for Medicinal Plant and Natural ...
(Date:1/14/2014)... In recent years, growing suspicion about ... product development and promotion has led to unprecedented levels ... by concerns about the insidious impact of commercialization of ... fines to the world’s biggest pharmas for illegal marketing ...
(Date:1/14/2014)... , Jan. 14, 2014   Kinaxis ®, provider of ... and sales and operations planning ( S&OP ) service, is ... Summit , which will be held at the Hilton San ... join Kinaxis customer Elisabeth Kaszas , Director of Supply ...
(Date:1/14/2014)... NY (PRWEB) January 14, 2014 During the ... now known as “The Doctor’s Plague.” In this time period, ... hands. This led, at times, to the death of vulnerable ... today don’t know that they may be unwittingly transmitting herpes ...
Breaking Biology Technology:World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 2World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 3World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 4World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 5World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 6World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 7World's Largest Group of Medicinal Plant Researchers Endorses ABC-AHP-NCNPR Botanical Adulterants Program 8The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 2The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 3Event Alert: Kinaxis Customer to Present at the Biomanufacturing Summit "Supply Chain: Improving Network Effectiveness" 2Study: Fatigued Medical Interns Infect Their Patients with Herpes Viruses; The CBCD Sees a Parallel with “The Doctor’s Plague” 2Study: Fatigued Medical Interns Infect Their Patients with Herpes Viruses; The CBCD Sees a Parallel with “The Doctor’s Plague” 3
... 2011 TriLink BioTechnologies, Inc. (TriLink) announced that it ... (TATAA) to sell its CleanAmp™ Products. The Scandinavian based ... qPCR courses worldwide, in addition to providing tailor-made products ... innovative approach to Hot Start PCR, TriLink,s CleanAmp™ Product ...
... March 25, 2011 BioNeutral Group, Inc. (OTC Bulletin ... technology-based company, today announced the appointment of Dr. Stephen ... and a medical practitioner in New York State, as ... Director. Dr. Holt is an independent consultant to the ...
... Diagnostic Laboratory, Inc. (HDL, Inc.) and BG Medicine, Inc. (Nasdaq: ... HDL, Inc. will offer galectin-3 testing services based on the ... Galectin-3 Test was recently cleared by the FDA as an ... failure. Elevated galectin-3 levels are associated with an inherently progressive ...
Cached Biology Technology:TriLink Enters Into Distribution Agreement With TATAA Biocenter 2BioNeutral Elects Stephen Holt, M.D., Ph.D as Vice Chairman and Independent Director of the Board 2BioNeutral Elects Stephen Holt, M.D., Ph.D as Vice Chairman and Independent Director of the Board 3Health Diagnostic Laboratory, Inc. (HDL, Inc.) Announces Availability of Galectin-3 Testing Service in Partnership With BG Medicine 2Health Diagnostic Laboratory, Inc. (HDL, Inc.) Announces Availability of Galectin-3 Testing Service in Partnership With BG Medicine 3Health Diagnostic Laboratory, Inc. (HDL, Inc.) Announces Availability of Galectin-3 Testing Service in Partnership With BG Medicine 4
(Date:4/23/2014)... Heidelberg, 23 April 2013 EMBO today announced Sophie ... winner of the 2014 EMBO Gold Medal. The award ... define the organization and development of the cell. , ... to understand cellular polarity, in particular the way in ... size and cell division. In the last 11 years, ...
(Date:4/23/2014)... at the University of Houston (UH) is working to ... His work is supported by a $1.8 million grant ... Blood transfusions save millions of lives every year. They ... for instance, routine surgeries would become life threatening. This ... that transfusions of red blood cells stored in a ...
(Date:4/23/2014)... London (April 23, 2014). "I think one can argue that ... well as doing everything else that we canthen we can ... Wigley, one of the world,s foremost climate researchers, in the ... published by SAGE. Refusing to take significant action on climate ... be needed to address the problem, Wigley explains in an ...
Breaking Biology News(10 mins):EMBO Gold Medal 2014 awarded to Sophie Martin 2UH biomedical engineer works to make blood transfusions safer 2UH biomedical engineer works to make blood transfusions safer 3Is nuclear power the only way to avoid geoengineering? 2
... 2012) Autologous (self-donated) mononuclear cells derived from bone ... growth when transplanted into patients with diabetes who are ... disease (PAD), a complication of diabetes. The team of ... published their results in a recent issue of ...
... of people to punish others who lie, cheat, steal or ... don,t stand to benefit personally, is a distinctly human behavior. ... behave in this "I punish you because you harmed him" ... long been institutionalized in human legal systems and economists have ...
... NJIT signed a cooperation agreement with the Bengbu ... and research and development at a recent ceremony at ... People,s Republic of China, New York, were present. ... executives of the Bengbu Institute. In addition, the ...
Cached Biology News:Autologous bone marrow-derived mononuclear cell transplants can reduce diabetic amputations 2Crime and punishment: The neurobiological roots of modern justice 2Crime and punishment: The neurobiological roots of modern justice 3Crime and punishment: The neurobiological roots of modern justice 4Crime and punishment: The neurobiological roots of modern justice 5NJIT, China's Bengbu Glass Institute sign agreement for R&D, training 2
... DNA from plants in 96 well plates. Plant materials ... plate using large zirconia beads optimized for even tough ... (available through Mo Bio). Cells are lysed and DNA ... The DNA is washed and then released into 10 ...
... protein array systems, known as ChemiArrayTM ... useful compared with current methodologies. Besides ... Chemicons systems present a more accurate ... they only detect secreted cytokines, and ...
Request Info...
... The Gene Pulser Xcell microbial system, ... is used for electroporation of bacterial ... the main unit, PC module for ... 10 sterile cuvettes (5 each of ...
Biology Products: